Colorectal Cancer Clinical Trial
Official title:
A Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre Study
RATIONALE: Fiber may lessen bowel side effects caused by radiation therapy. It is not yet
known whether a high-fiber diet is more effective than a low-fiber diet in preventing bowel
side effects caused by radiation therapy.
PURPOSE: This randomized clinical trial is studying a high-fiber diet to see how well it
works compared with a low-fiber diet in preventing bowel side effects in patients undergoing
radiation therapy for gynecological cancer, bladder cancer, colorectal cancer, or anal
cancer.
OBJECTIVES:
Primary
- To compare the efficacy of a high- vs low-fiber intervention in preventing bowel
toxicity in patients receiving radical pelvic radiotherapy treatment for gynecological,
urological (bladder), colorectal, or anal malignancy.
- To compare whether a high- or low-fiber intervention has any beneficial effect over no
intervention (i.e., ad-libitum fiber consumption).
- To examine the effect of a low- or high-fiber diet on gastrointestinal symptoms,
measured using the IBDQ-B and Bristol Stool Chart, in patients receiving radical
radiotherapy for pelvic malignancies.
- To minimize any potential risk associated with change in fiber intake by using a
controlled and gradual dietary-based intervention combined with dietetic advice.
Secondary
- To examine the relationship between volume of irradiated bowel and onset of
gastrointestinal symptoms as measured by the Bristol Stool Chart.
- To measure percentage compliance with fiber prescription through validated dietetic
techniques including the 7-day Food Diary using household measures and the 24-hour
recall.
OUTLINE: Patients are stratified according to disease (gynecological vs gastrointestinal)
and concomitant therapy (received vs not received). Patients are randomized to 1 of 3
treatment arms.
- Arm I (low-fiber diet): Patients are assessed by a qualified dietitian, receive written
guidance, and are counseled as to how best to meet their study fiber prescription of a
low-fiber diet, comprising 'not more than' 10 g of fiber per day for up to 7 weeks.
- Arm II (high-fiber diet): Patients are assessed by a qualified dietitian, receive
written guidance, and are counseled as to how best to meet their study fiber
prescription of a high-fiber diet, comprising a target of between 18 and 22 g of fiber
per day for up to 7 weeks.
- Arm III (no intervention): Patients receive advice designed to ensure they maintain
their normal habitual diet for up to 7 weeks.
All patients undergo radiotherapy once daily comprising approximately 25 (or more) fractions
in total to be delivered for 5-7 weeks in the absence of unacceptable toxicity.
All patients are asked to complete two 7-day Food Diaries at baseline and end of
radiotherapy treatment. All patients keep a daily record of stool characteristics and
frequency using the Bristol Stool Chart. Patients also complete a short 1-page weekly-cost
questionnaire to assess the economic impact of symptom management. Patients in arms I and II
complete several additional questions regarding the costs (if any) of adhering to their
fiber prescription and the palatability of the diet.
Blood and stool samples may be collected at baseline and during study therapy for biomarker
analysis.
After completion of study treatment, patients are followed up for up to 1 year.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |